Applied DNA Reports First Quarter Fiscal 2025 Financial Results and Highlights Operational Progress
In December 2024, the Company announced a strategic restructuring of its business operations, including the potential divestiture of its DNA Tagging and Security Products and Services ("DNA Tagging") ...
The EMBO Journal16h
Portimine A toxin causes skin inflammation through ZAKα-dependent NLRP1 inflammasome activation
In 2020-2021, a mysterious skin disease affected fishermen in Senegal. High levels of Portimine A toxin, produced by the ...
PulseSight Therapeutics Announces First Close of its Series A Financing to Fund Clinical Development of PST-611 in dry AMD
PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, today announces the first close of its ...